Disclosure
This article contains an affiliate link. Zenni Optical runs an affiliate programme we participate in, and we may earn a commission if you buy through our link. Zenni sells prescription eyewear — it is not a health service, it does not perform eye examinations, and nothing it sells detects or treats any of the conditions described below. Read our full affiliate disclosure.
This page is informational only and is not medical advice.
The short version
NAION. European regulators concluded in June 2025 that this rare form of sudden, usually permanent vision loss is a very rare side effect of semaglutide — up to 1 in 10,000 people. Sudden loss of vision in one eye means calling your doctor the same day.
Diabetic retinopathy. A real signal in the semaglutide trials, concentrated in people who already had retinopathy and whose blood sugar fell fastest. Relevant if you have diabetes; not relevant if you do not.
Your glasses prescription. It will move while your glucose is moving. Wait until it settles before buying anything expensive.
NAION: The Regulators Have Acted
This is the one that changed a drug label. On 6 June 2025, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee concluded that non-arteritic anterior ischaemic optic neuropathy — NAION — is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it, and recommended updating the product information for Ozempic, Rybelsus and Wegovy accordingly. PRAC put the epidemiological estimate at approximately one additional case of NAION per 10,000 person-years of treatment.
The committee reached that conclusion after reviewing non-clinical studies, clinical trials, post-marketing surveillance and the published literature. Its summary of the evidence is worth repeating precisely, because the studies disagree with each other: large epidemiological studies showed roughly a two-fold increased risk compared with non-users, while clinical trial data pointed to a slightly higher risk versus placebo.
What NAION actually is
NAION is a loss of blood supply to the head of the optic nerve. It typically presents as sudden, painless loss of vision in one eye, often first noticed on waking. It is not gradual, it is not fluctuating, and it does not usually hurt. The damage is generally permanent.
The regulatory advice is direct: if you experience a sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide, contact your doctor without delay. If NAION is confirmed, semaglutide should be stopped.
How the evidence got here, and why the numbers vary so much
The alarm was raised by a study from Massachusetts Eye and Ear, published in JAMA Ophthalmology in 2024. It was a single-centre retrospective matched cohort of patients seen by a neuro-ophthalmology service, and the hazard ratios were striking: 4.28 (95% CI 1.62–11.29) in the type 2 diabetes cohort and 7.64 (95% CI 2.21–26.36) in the overweight and obese cohort.
Those are large numbers from a small, specialised population — patients who had already been referred to a neuro-ophthalmology service, at one centre. The counterweight arrived in February 2025, when JAMA Ophthalmology published a multi-database population study covering 37.1 million adults with type 2 diabetes, including 810,390 new semaglutide users. It found an incidence rate ratio of 1.32 — a 32% relative increase, far below the earlier figure. The trade-off is diagnostic precision: database studies cannot match manual chart review for confirming that a case of NAION really was NAION.
Both things can be true. The relative risk is real and the absolute risk is low. The authors of the larger study said so themselves: patients should not stop taking semaglutide on this account alone, given the drug's cardiovascular and metabolic benefits. What has changed is that you now have a symptom worth recognising.
One geographic note. The June 2025 label change was a European action. When we checked, the US labels for these products had not been revised in the same way. That is a difference in regulatory process, not a difference in the underlying evidence — the studies above are the same studies wherever you live.
Diabetic Retinopathy and the Speed of the Drop
This is a separate issue with a separate mechanism, and it applies to people with diabetes. In SUSTAIN-6, the cardiovascular outcomes trial of semaglutide, diabetic retinopathy complications — vitreous haemorrhage, blindness, or conditions requiring intravitreal treatment or photocoagulation — occurred more often on semaglutide than placebo, with a hazard ratio of 1.76 (95% CI 1.11–2.78, p=0.02).
The follow-up analysis is the important part. The imbalance was concentrated in patients who already had diabetic retinopathy at baseline and patients on insulin, and post-hoc work pointed at the size of the HbA1c reduction as a main driver. In other words, this looks like early worsening from rapid glycaemic improvement — a phenomenon ophthalmologists have recognised for decades in other contexts — rather than something the drug does directly to the retina. Long-term glucose control protects the retina. Getting there very quickly can cause a temporary deterioration first in eyes that are already damaged.
For tirzepatide the picture is less alarming and less complete. A retinal substudy of SURPASS-CVOT found no difference between groups in retinopathy progression, interventions, complications, or sustained visual acuity loss. But the SURPASS trials excluded people with moderate non-proliferative diabetic retinopathy or worse — which is to say, they excluded exactly the people the semaglutide signal was concentrated in. Real-world cohort studies are only now filling that gap.
What to do with this
If you have type 2 diabetes and any degree of retinopathy, raise it with your prescriber before you start, and ask whether a dilated eye examination should come first. Knowing your retinal status is what lets a clinician judge how quickly to escalate your dose.
If you do not have diabetes, diabetic retinopathy is not your issue. The NAION section above is the one that applies to you.
The Boring One: Your Prescription Will Move
Here is the change almost everybody gets and almost nobody is warned about. When blood glucose rises or falls quickly, fluid shifts inside the lens of the eye and changes its refractive power. In poorly controlled diabetes that shift has been measured at several dioptres of induced myopia or hyperopia — more than enough to make the world go soft. It resolves as glucose stabilises, usually over a few weeks, sometimes with mild headaches while your eyes readjust.
Dose escalation on a GLP-1 is precisely the period when your glucose is moving. So the standard advice applies with force: do not get your eyes tested for a new prescription in the middle of it, and do not buy expensive lenses off a measurement taken then. Wait until your blood sugar has been steady for at least a couple of weeks before the exam.
- Fluctuating blur that comes and goes — most likely glucose-driven refractive change. Annoying, temporary, not an emergency.
- Sudden loss of vision in one eye, usually painless — this is the NAION presentation. Call your doctor the same day.
- New floaters, flashes, or a curtain across your vision — get seen urgently, whatever you are taking.
- Gradual change over months as your weight settles — the point at which a proper eye test and a proper pair of glasses make sense.
There is a second, purely mechanical problem. Losing 15–20% of your body weight changes the shape of your face, and frames that fitted at the start of treatment can sit differently a year in — the same effect behind what the internet calls Ozempic face. It is the eyewear version of the wardrobe problem covered in our piece on clothes and body image on a GLP-1, and it has the same answer: bridge cheaply, buy properly once things stop moving.
Where Cheap Glasses Actually Make Sense
This is one of the few situations where buying the cheap pair is the informed choice rather than the compromise. You need to see properly for the next few months; you know the prescription is provisional; spending several hundred dollars on lenses you will replace is simply wasted money.
Zenni Optical is the obvious candidate for that job. It sells online only, with frames starting at $6.95, and its base price includes the frame, the lenses, anti-scratch coating, UV protection, a case and a cleaning cloth rather than treating those as add-ons. US standard shipping is $4.95, taking 7–14 business days. Returns run on two tracks: within 14 days of delivery you can have a refund to your original payment method, minus shipping, and within 30 days you can take store credit instead. Broken frames are replaced free during a 30-day warranty period, and defects in anti-reflective coatings and photochromic films are warrantied for a year.
You will need two things before ordering: a valid prescription from an eye care professional, and your pupillary distance. Zenni does not perform eye examinations — it fills prescriptions other people write. If your prescription does not include your PD, it can be measured, but an inaccurate PD is the single most common reason online glasses arrive wrong.
The important caveat
Buying glasses online is not a substitute for an eye examination, and on a GLP-1 that distinction matters more than usual. Neither NAION nor diabetic retinopathy is detectable from a spectacle prescription. Both are found by a clinician looking at the back of your eye.
The right use of a cheap pair is as a bridge between an examination you have already had and a prescription that has not yet settled. The wrong use is skipping the examination because the glasses were cheap.
Eyewear retailer · Not a health service · No eye exams · Prescription and PD required
A short checklist
- Know the NAION warning sign: sudden, usually painless loss of vision in one eye. Same-day call.
- If you have diabetes, tell your prescriber about any retinopathy before you start, and ask about a dilated exam.
- Expect fluctuating blur during titration. It is normal and it passes.
- Do not get tested for a new prescription until your blood sugar has been steady for a couple of weeks.
- Bridge with a cheap pair; buy properly once your prescription and your face have settled.
- Keep the routine eye exams. The cheap glasses do not replace them.
Frequently Asked Questions
Can Ozempic or Wegovy cause blindness?
European regulators concluded there is a real but very rare risk. On 6 June 2025 the EMA's Pharmacovigilance Risk Assessment Committee concluded that NAION — a form of sudden, usually permanent vision loss — is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it, and recommended adding it to the product information for Ozempic, Rybelsus and Wegovy. Epidemiological data pointed to roughly one additional case per 10,000 person-years of treatment. "Very rare" is doing real work in that sentence: this is a serious outcome at a low absolute rate, not a common one.
What is NAION and how would I know if I had it?
NAION stands for non-arteritic anterior ischaemic optic neuropathy. It is a loss of blood supply to the optic nerve head, and it typically presents as sudden, painless loss of vision in one eye, often noticed on waking. It is not blurriness that comes and goes and it is not eye strain. The damage is usually permanent. The EMA's advice is unambiguous: if you experience a sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide, contact your doctor without delay, and if NAION is confirmed, semaglutide should be stopped.
Should I stop my GLP-1 because of the eye risk?
Not on your own, and not on the basis of this article. The researchers behind the largest study of the question — 37.1 million adults across 14 databases, published in JAMA Ophthalmology in February 2025 — concluded that patients should not stop taking semaglutide on this account alone, given the drug's cardiovascular and metabolic benefits. That study found a much smaller effect than the one that started the alarm. The sensible response is to know the warning sign, act fast if you see it, and have the conversation with your prescriber rather than making the decision alone.
Why has my vision gone blurry since I started?
Most likely because your blood sugar has moved. Glucose changes shift fluid levels in the lens of the eye, which changes its refractive power — in poorly controlled diabetes the swing can be several dioptres, enough to make you notice. It is temporary, it settles as your glucose stabilises, and it is a well-documented phenomenon that long predates these medications. What it is not is a reason to rush out and buy glasses, because the prescription you measure this week will be wrong in a month. Fluctuating blur is different from sudden loss of vision in one eye — the second is the one that needs a same-day call.
When should I get new glasses on a GLP-1?
After your blood sugar has been stable for at least a couple of weeks, not during rapid change. That is standard advice for anyone whose glucose is moving, and dose escalation on a GLP-1 is exactly that situation. The practical version: if you need to see properly right now, buy something cheap as a bridge, and save the proper purchase for when your prescription has settled. Frames are a separate issue — substantial weight loss changes the shape of your face, so a pair that fit at the start of treatment may sit differently a year in.
Do I need an eye exam before starting a GLP-1?
If you have type 2 diabetes, this is worth raising with your prescriber, and particularly so if you already have any diabetic retinopathy. The retinopathy signal in the semaglutide trials was concentrated in people who had retinopathy at baseline, were on insulin, and had the largest falls in HbA1c. Knowing your retinal status before you start is what lets your clinician weigh that. If you do not have diabetes, diabetic retinopathy is not your concern — but knowing your baseline vision is still useful, because it is what makes a change obvious.
Where to Go Next
- GLP-1 side effects guide — the full picture, including what is common versus what is rare and serious
- Diabetes, obesity and hearing loss — the other sensory system with a metabolic story
- Ozempic face — why facial change happens and what it does to how things fit
Medical Disclaimer
We're not doctors, and this article is for education only — it isn't medical advice. GLP-1 medications are prescription-only and require evaluation by a licensed healthcare provider. Individual results vary widely, and only a clinician who knows your history can determine what is safe and appropriate for you. See our full medical disclaimer.
Keep Comparing
Every provider we've researched, with published pricing, medication type, and what's actually included.
Affiliate Disclosure: This article may contain affiliate links. If you sign up through one, we may earn a commission at no additional cost to you. We do not accept payment for favorable coverage. Read our full affiliate disclosure policy.